INVESTOR CONTACT:
|
A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
+1 (978) 421-9655
|
ZOLL MEDICAL CORPORATION TO PARTICIPATE IN CONFERENCE CALL HOSTED BY JEFFERIES & COMPANY
August 11, 2011─CHELMSFORD, MASS.–ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, today announced that it will participate in a conference call hosted by Jefferies & Company on Friday, August 12, 2011 at 11:00 a.m. (EDT) to discuss an update on recent business issues. The call will be hosted by Jefferies Medical Devices Analyst, Raj Denhoy. ZOLL CEO, Richard A. Packer, will offer additional comments. Jefferies has arranged for a physician of their choosing to join the discussion.
To participate in the call:
11:00 AM EDT / 04:00 PM BST, Friday, August 12, 2011
U.S. Dial-in: 866-900-5944
Global Dial-in: 706-643-3801
U.K. Dial-in: +44 (0) 20 3107 0289
Conference ID#: 91510989
A replay will be available starting approximately two hours after the conclusion of the call until August 19, 2011.
REPLAY: 855-859-2056 or 404-537-3406 for international callers.
Conference ID#: 91510989
About ZOLL Medical Corporation
ZOLL Medical Corporation develops and markets medical devices and related software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.
A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company for the past three years, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.
Certain statements contained in this press release, including statements regarding the anticipated development of the Company's business, our belief regarding revenues, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-K filed with the SEC on December 17, 2010. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.
© 2011 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. AutoPulse, LifeVest, and ZOLL are registered trademarks of ZOLL Medical Corporation. All trademarks are property of their respective owners.
ZOLL MEDICAL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
|
April 3, 2011
|
October 3, 2010
|
ASSETS
|
|
|
Current assets:
|
|
|
Cash and cash equivalents
|
$ 55,743
|
$ 59,058
|
Short-term investments
|
1,660
|
3,203
|
Accounts receivable, net
|
93,515
|
99,543
|
Inventory
|
69,314
|
69,958
|
Prepaid expenses and other current assets
|
25,720
|
24,649
|
Total current assets
|
245,952
|
256,411
|
Property and equipment, net
|
59,328
|
49,923
|
Other assets, net
|
122,066
|
124,436
|
|
$ 427,346
|
$ 430,770
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
Current and other liabilities:
|
|
|
Accounts payable
|
$ 20,041
|
$ 22,801
|
Accrued expenses and other liabilities
|
73,901
|
94,391
|
Total liabilities
|
93,942
|
117,192
|
Total stockholders’ equity
|
333,404
|
313,578
|
|
$ 427,346
|
$ 430,770
|
ZOLL MEDICAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
|
Three Months Ended
|
Six Months Ended
|
|
April 3,
2011
|
April 4,
2010
|
April 3,
2011
|
April 4,
2010
|
Net sales
|
$ 122,495
|
$ 107,058
|
$ 235,657
|
$ 212,270
|
Cost of goods sold
|
|
|
|
|
Gross profit
|
71,363
|
58,700
|
132,713
|
114,871
|
Expenses:
|
|
|
|
|
Selling and marketing
|
39,240
|
32,472
|
74,022
|
64,083
|
General and administrative
|
11,843
|
9,403
|
22,215
|
18,914
|
Research and development
|
|
|
|
|
Total expenses
|
62,182
|
53,167
|
118,174
|
105,652
|
Income from operations
|
9,181
|
5,533
|
14,539
|
9,219
|
Other income
|
|
|
|
|
Income before taxes
|
9,634
|
5,781
|
15,256
|
9,445
|
Tax expense
|
|
|
|
|
Net income
|
|
|
|
|
Earnings per share:
|
|
|
|
|
Basic
|
|
|
|
|
Diluted
|
|
|
|
|
Weighted average common shares:
|
|
|
|
|
Basic
|
21,747
|
21,369
|
21,666
|
21,292
|
Diluted
|
22,467
|
21,759
|
22,294
|
21,625
|